# NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Files Abbreviated New Drug Application for Preservative-Free IV Ketamine NRX-100 Amid Ongoing Shortage

* The company targets all current ketamine indications, including anesthesia and pain management.
* The U.S. is facing a severe ketamine shortage, prompting NRx to seek priority FDA review.
* NRX-100 eliminates benzethonium chloride, aligning with U.S. health initiatives to remove toxic preservatives.
* The company plans to petition the FDA to remove benzethonium chloride from all intravenous ketamine products.
* The filing complements the company’s NDA for NRX-100 for suicidal depression, with a PDUFA date expected in late 2025.

 NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, has filed an Abbreviated New Drug Application with the U.S. Food and Drug Administration for NRX-100, a preservative-free formulation of ketamine. The submission seeks approval for all existing ketamine indications, including its use in anesthesia and pain management (https://ibn.fm/hsgzo).

 The move comes amid a significant shortage of ketamine in the United States, as noted by the American Society of Health-System Pharmacists. With demand rising and supply constrained, the company is…

 Read More>>

 NOTE TO INVESTORS: The latest news and updates relating to NRXP are available in the company’s newsroom at https://ibn.fm/NRXP

 About PsychedelicNewsWire

 PsychedelicNewsWire (“PNW”) is a specialized communications platform with a focus on all aspects of psychedelics and the latest developments and advances in the psychedelics sector. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, PNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, PNW brings its clients unparalleled recognition and brand awareness. PNW is where breaking news, insightful content and actionable information converge.

 To receive SMS alerts from PsychedelicNewsWire, text “Groovy” to 888-902-4192 (U.S. Mobile Phones Only)

 For more information, please visit https://www.PsychedelicNewsWire.com

 Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer

 PsychedelicNewsWireSan Francisco, CAwww.PsychedelicNewsWire.com415.949.5050 OfficeEditor@PsychedelicNewsWire.com

 PsychedelicNewsWire is powered by IBN 

---

[Original/Source Press Release](https://rss.investorbrandnetwork.com/pnw/nrx-pharmaceuticals-inc-nasdaq-nrxp-files-abbreviated-new-drug-application-for-preservative-free-iv-ketamine-nrx-100-amid-ongoing-shortage/)
                    

[Newsramp.com TLDR](https://newsramp.com/curated-news/nrx-pharmaceuticals-seeks-fda-approval-for-preservative-free-ketamine-amid-shortage/98c59877a72338f3925b71969c841174) 

 



[Reddit Post](https://www.reddit.com/r/PsychedelicsNews/comments/1l9tyyh/nrx_pharmaceuticals_seeks_fda_approval_for/) 



![Blockchain Registration](https://cdn.newsramp.app/ibn/qrcode/256/12/mint_AjX.webp)